The Enhanced Renin-Angiotensin-Aldosteron System Pharmacological Blockade - Which is the Best? | Zendy

Leszek Tylicki | Zendy; Sławomir Lizakowski | Zendy; Przemysław Rutkowski | Zendy; Marcin Renke | Zendy; Beata Sulikowska | Zendy; Zbigniew Heleniak | Zendy; Rafał Donderski | Zendy; Rafał Bednarski | Zendy; Milena Przybylska | Zendy; Jacek Manitius | Zendy; Piotr Rutkowski | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Enhanced Renin-Angiotensin-Aldosteron System Pharmacological Blockade - Which is the Best?

Author(s) -

Leszek Tylicki,

Sławomir Lizakowski,

Przemysław Rutkowski,

Marcin Renke,

Beata Sulikowska,

Zbigniew Heleniak,

Rafał Donderski,

Rafał Bednarski,

Milena Przybylska,

Jacek Manitius,

Piotr Rutkowski

Publication year - 2012

Publication title -

kidney and blood pressure research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.806

H-Index - 51

eISSN - 1423-0143

pISSN - 1420-4096

DOI - 10.1159/000343391

Subject(s) - telmisartan , medicine , albuminuria , urology , aliskiren , eplerenone , combination therapy , irbesartan , pharmacology , endocrinology , losartan , proteinuria , mineralocorticoid receptor , amlodipine , ramipril , lisinopril , blood pressure , renin–angiotensin system , aldosterone , angiotensin converting enzyme , kidney

Pharmacological inhibition of renin-angiotensin-aldosteron system (RAAS) may reduce proteinuria and the rate of chronic kidney disease progression. The aim was to compare the effects on albuminuria of the therapy with either: (i) telmisartan 80 mg and aliskiren 300 mg, (ii) telmisartan 80 mg and eplerenone 50 mg, (iii) telmisartan 160 mg as monotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research